Bioventus Inc. (BVS) Bundle
Understanding Bioventus Inc. (BVS) Revenue Streams
Understanding Bioventus Inc.’s Revenue Streams
Bioventus Inc. generates revenue primarily from three business segments: Pain Treatments, Surgical Solutions, and Restorative Therapies. The following table outlines the net sales for these segments for the three and nine months ended September 28, 2024, and September 30, 2023.
| Segment | Three Months Ended September 28, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Nine Months Ended September 28, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|---|---|
| Pain Treatments | $63,127 | $53,690 | $192,076 | $161,657 |
| Restorative Therapies | $29,937 | $28,328 | $92,031 | $99,355 |
| Surgical Solutions | $45,900 | $38,776 | $121,275 | $102,131 |
| Total Net Sales | $138,964 | $120,794 | $419,638 | $376,922 |
Year-over-year revenue growth rates show significant increases across the segments. For the three months ended September 28, 2024, total net sales increased by 15.0% compared to the same period in the previous year. The breakdown of revenue growth by segment is as follows:
- Pain Treatments: Increased by 17.0% year-over-year.
- Restorative Therapies: Increased by 5.7% year-over-year.
- Surgical Solutions: Increased by 18.6% year-over-year.
For the nine months ended September 28, 2024, total net sales grew by 11.3% year-over-year, with the following contributions:
- Pain Treatments: Increased by 18.7%.
- Restorative Therapies: Decreased by 6.8%.
- Surgical Solutions: Increased by 18.7%.
The contribution of different business segments to overall revenue is illustrated in the following table:
| Segment | Contribution to Total Revenue (Q3 2024) |
|---|---|
| Pain Treatments | 45.4% |
| Restorative Therapies | 21.5% |
| Surgical Solutions | 33.1% |
Significant changes in revenue streams have occurred due to the divestiture of the Wound Business, which affected the Restorative Therapies segment. This divestiture led to a decline of $5.7 million in revenue for Restorative Therapies in the nine months ended September 28, 2024.
Overall, the revenue analysis indicates a healthy growth trajectory in Pain Treatments and Surgical Solutions, while the Restorative Therapies segment faces challenges due to the divestiture. The company is focusing on optimizing its product mix and improving operational efficiencies to enhance revenue streams moving forward.
A Deep Dive into Bioventus Inc. (BVS) Profitability
Profitability Metrics
The financial health of the company can be assessed through various profitability metrics, including gross profit, operating profit, and net profit margins. The following summarizes these key indicators for the most recent fiscal year.
Gross Profit and Gross Margin
For the three months ended September 28, 2024, the total gross profit was $93,551,000, compared to $78,850,000 for the same period in the previous year, reflecting an increase of 18.6%. The gross margin for this period was 67.3%, up from 65.3% year-over-year.
In the nine months ended September 28, 2024, the total gross profit reached $285,570,000, compared to $241,892,000 in the prior year, marking an increase of 18.1%. The gross margin for this period was 68.1%, compared to 64.2% in the previous year.
| Period | Gross Profit ($) | Gross Margin (%) |
|---|---|---|
| Three Months Ended September 28, 2024 | $93,551,000 | 67.3% |
| Three Months Ended September 30, 2023 | $78,850,000 | 65.3% |
| Nine Months Ended September 28, 2024 | $285,570,000 | 68.1% |
| Nine Months Ended September 30, 2023 | $241,892,000 | 64.2% |
Operating Profit
The operating income for the three months ended September 28, 2024, was $4,074,000, compared to $2,418,000 for the same period in 2023. The operating loss for the nine months ended September 28, 2024, was $(19,967,000), an improvement from the operating loss of $(82,890,000) in the prior year.
Net Profit Margin
For the three months ended September 28, 2024, the net loss was $(5,421,000), translating to a net loss margin of (3.9%). In comparison, the net loss for the three months ended September 30, 2023, was $(8,791,000), with a net loss margin of (7.3%).
For the nine months ended September 28, 2024, the net loss was $(43,515,000), resulting in a net loss margin of (10.4%), compared to a net loss of $(113,540,000) for the same period in 2023, which had a net loss margin of (30.1%).
| Period | Net Loss ($) | Net Margin (%) |
|---|---|---|
| Three Months Ended September 28, 2024 | $(5,421,000) | (3.9%) |
| Three Months Ended September 30, 2023 | $(8,791,000) | (7.3%) |
| Nine Months Ended September 28, 2024 | $(43,515,000) | (10.4%) |
| Nine Months Ended September 30, 2023 | $(113,540,000) | (30.1%) |
Trends in Profitability Over Time
Over the last fiscal year, the company has shown improvement in gross profit and margins, reflecting operational efficiencies and increased sales volumes across various segments. The operating loss has narrowed significantly, indicating better cost management and operational strategies.
Comparison of Profitability Ratios with Industry Averages
As of September 2024, the company’s gross margin of 67.3% compares favorably against the industry average of approximately 60%. The net margin of (3.9%) indicates a loss, but it is an improvement from the previous year and is competitive with industry peers experiencing similar recovery phases.
Analysis of Operational Efficiency
Cost management strategies have led to a 16.1% increase in selling, general and administrative expenses, amounting to $81,090,000 for the three months ended September 28, 2024. Research and development expenses also increased by 26.3% to $3,808,000, reflecting ongoing investments in innovation.
The adjusted EBITDA for the three months ended September 28, 2024, was $23,557,000, an increase from $21,735,000 in the previous year.
| Period | Adjusted EBITDA ($) |
|---|---|
| Three Months Ended September 28, 2024 | $23,557,000 |
| Three Months Ended September 30, 2023 | $21,735,000 |
| Nine Months Ended September 28, 2024 | $80,632,000 |
| Nine Months Ended September 30, 2023 | $66,844,000 |
Debt vs. Equity: How Bioventus Inc. (BVS) Finances Its Growth
Debt vs. Equity: How Bioventus Inc. Finances Its Growth
As of September 28, 2024, Bioventus Inc. reported total liabilities of $582.7 million. This includes current liabilities of $211.5 million and long-term debt of $345.0 million .
Overview of the Company's Debt Levels
Bioventus Inc. has a mix of short-term and long-term debt. The current portion of long-term debt amounts to $38.6 million, while the long-term debt, less current portion, is $345.0 million .
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for Bioventus Inc. stands at approximately 3.09, calculated from total debt of $345.0 million and total stockholders' equity of $186.8 million as of September 28, 2024 . This ratio is significantly above the industry average of approximately 1.5, indicating a higher reliance on debt financing compared to equity .
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
On January 18, 2024, Bioventus amended its 2019 Credit Agreement to modify certain financial covenants. The company also has outstanding borrowings of $15.0 million on its Revolver, with total capacity reduced to $40.0 million . The estimated fair value of the Term Loan Facilities was $372.1 million as of September 28, 2024 .
How the Company Balances Between Debt Financing and Equity Funding
Bioventus has utilized proceeds from the divestiture of its Wound Business, amounting to $84.7 million, to prepay $30.0 million of long-term debt . This strategic move highlights the company's approach to balance its debt levels while maintaining liquidity. The company's cash and cash equivalents stood at $43.1 million as of September 28, 2024 .
| Financial Metric | September 28, 2024 | Industry Average |
|---|---|---|
| Total Liabilities | $582.7 million | N/A |
| Current Liabilities | $211.5 million | N/A |
| Long-Term Debt | $345.0 million | N/A |
| Debt-to-Equity Ratio | 3.09 | 1.5 |
| Cash and Cash Equivalents | $43.1 million | N/A |
| Revolver Borrowings | $15.0 million | N/A |
| Proceeds from Wound Business Sale | $84.7 million | N/A |
| Long-Term Debt Prepayment | $30.0 million | N/A |
Assessing Bioventus Inc. (BVS) Liquidity
Assessing Liquidity
Current Ratio: As of September 28, 2024, the current ratio is calculated at 1.41, indicating that the company has sufficient current assets to cover its current liabilities.
Quick Ratio: The quick ratio stands at 0.93, suggesting potential liquidity concerns, as it indicates that current assets excluding inventory are close to current liabilities.
Working Capital Trends
The working capital as of September 28, 2024, is $87,196 thousand, compared to $92,502 thousand as of December 31, 2023, reflecting a decrease in available working capital.
| Period | Current Assets (in $ thousands) | Current Liabilities (in $ thousands) | Working Capital (in $ thousands) |
|---|---|---|---|
| September 28, 2024 | 298,688 | 211,492 | 87,196 |
| December 31, 2023 | 267,999 | 175,497 | 92,502 |
Cash Flow Statements Overview
Operating Cash Flow: For the nine months ended September 28, 2024, net cash from operating activities was $19,473 thousand, a significant increase from $4,970 thousand in the same period of 2023.
Investing Cash Flow: In the same period, cash used in investing activities totaled ($1,141) thousand, compared to $27,904 thousand in the prior year, highlighting a notable shift in investment strategy.
Financing Cash Flow: Cash flows from financing activities amounted to ($11,725) thousand, demonstrating a decrease from ($26,639) thousand in 2023, indicating reduced reliance on external financing.
| Cash Flow Type | 2024 (in $ thousands) | 2023 (in $ thousands) |
|---|---|---|
| Operating Activities | 19,473 | 4,970 |
| Investing Activities | (1,141) | 27,904 |
| Financing Activities | (11,725) | (26,639) |
Potential Liquidity Concerns or Strengths
Despite the positive operating cash flow trend, the quick ratio below 1 indicates potential liquidity concerns. The company’s reliance on external financing has decreased, suggesting a shift towards improving internal cash generation capabilities. The upcoming divestiture of the Advanced Rehabilitation Business, expected to close by early 2025, is projected to enhance liquidity further by providing additional cash inflows to reduce long-term debt obligations.
Is Bioventus Inc. (BVS) Overvalued or Undervalued?
Valuation Analysis
To assess whether Bioventus Inc. is overvalued or undervalued, we will analyze key financial ratios, stock price trends, dividend yield, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The price-to-earnings (P/E) ratio is a crucial indicator for valuation. As of recent reports, the P/E ratio stands at −12.38, indicating the company is currently not profitable.
Price-to-Book (P/B) Ratio
The price-to-book (P/B) ratio provides insight into the market's valuation compared to the company's book value. The current P/B ratio is 0.81.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value-to-EBITDA (EV/EBITDA) ratio is another significant metric. Currently, this ratio is approximately 6.95.
Stock Price Trends
Over the past 12 months, the stock price has seen fluctuations:
- 12 months ago: $7.50
- Current price: $4.85
- Price change: −35.33%
Dividend Yield and Payout Ratios
As of now, Bioventus does not pay a dividend, resulting in a dividend yield of 0%. Additionally, the payout ratio is not applicable due to the absence of dividend payments.
Analyst Consensus
According to the latest analyst ratings:
- Buy: 2
- Hold: 5
- Sell: 1
Summary Table of Valuation Metrics
| Metric | Value |
|---|---|
| P/E Ratio | −12.38 |
| P/B Ratio | 0.81 |
| EV/EBITDA Ratio | 6.95 |
| 12-Month Stock Price Change | −35.33% |
| Dividend Yield | 0% |
| Analyst Consensus (Buy/Hold/Sell) | 2/5/1 |
Key Risks Facing Bioventus Inc. (BVS)
Key Risks Facing Bioventus Inc.:
Bioventus Inc. faces a variety of internal and external risks that could impact its financial health. The following outlines key risk factors:
Industry Competition
The competitive landscape in the medical device industry is intense. Bioventus operates in a market characterized by rapid technological advancements and evolving customer preferences. The company reported a 12.2% increase in U.S. net sales year-over-year, totaling $371.6 million for the nine months ended September 28, 2024. However, the competitive pressure may compress margins and affect growth rates.
Regulatory Changes
Regulatory compliance is a significant factor for Bioventus, affecting product development timelines and market entry. The company must adhere to stringent regulations from bodies such as the FDA and international regulatory agencies. Any changes in these regulations could lead to increased costs or delays in product launches, impacting revenue and profitability.
Market Conditions
The overall market conditions, including economic downturns, could adversely affect sales. Bioventus reported a net loss from continuing operations of $43.5 million for the nine months ended September 28, 2024. Economic uncertainties may lead to reduced healthcare spending, affecting demand for its products.
Operational Risks
Operational risks include supply chain disruptions and manufacturing inefficiencies. For the three months ended September 28, 2024, the company incurred a gross profit of $93.6 million, representing a gross margin of 67.3%. Any significant operational disruptions could adversely affect these metrics.
Financial Risks
Financial risks, including high levels of debt, are a concern. As of September 28, 2024, Bioventus reported long-term debt obligations of $345.0 million. The company’s ability to service this debt is crucial, especially with ongoing net losses.
Strategic Risks
Strategic risks involve the company’s ability to execute its business model effectively. The planned divestiture of its Advanced Rehabilitation Business is projected to simplify operations and improve liquidity, with expected proceeds of $25.0 million at closing. However, divestitures can also pose risks if not managed properly, potentially leading to revenue loss.
Mitigation Strategies
Bioventus is taking steps to mitigate these risks through various strategies:
- Enhancing product development pipelines to stay competitive.
- Implementing cost control measures to manage operational expenses.
- Utilizing proceeds from divestitures to reduce debt and improve liquidity.
Summary Table of Financial Performance
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Sales | $138.964 million | $120.794 million | 15.0% increase |
| Gross Profit | $93.551 million | $78.850 million | 18.6% increase |
| Net Loss from Continuing Operations | $(5.421) million | $(8.791) million | 38.2% improvement |
| Long-term Debt | $345.021 million | $366.998 million | 5.7% decrease |
These risk factors and mitigation strategies are essential for investors to consider when evaluating the financial health of Bioventus Inc.
Future Growth Prospects for Bioventus Inc. (BVS)
Future Growth Prospects for Bioventus Inc.
Analysis of Key Growth Drivers
Bioventus Inc. is poised for growth driven by several key factors:
- Product Innovations: The company has focused on enhancing its existing product lines, particularly in Pain Treatments and Surgical Solutions. For instance, the volume growth in Durolane contributed to a $7.9 million increase in Pain Treatments net sales in the third quarter of 2024.
- Market Expansions: The international segment reported a 29.3% increase in Pain Treatments net sales, which underscores the potential for further market penetration.
- Acquisitions: Recent divestitures, including the Advanced Rehabilitation Business, are expected to streamline operations and improve liquidity. This business sold for $25 million at closing with additional potential earn-out payments.
Future Revenue Growth Projections and Earnings Estimates
Revenue growth is projected to continue as the company capitalizes on its core businesses:
| Period | Net Sales ($ in thousands) | Change ($ in thousands) | Change (%) |
|---|---|---|---|
| Q3 2024 | 138,964 | 18,170 | 15.0 |
| YTD 2024 | 419,638 | 42,716 | 11.3 |
The U.S. segment alone saw net sales increase by 12.2% year-over-year.
Strategic Initiatives or Partnerships that May Drive Future Growth
Strategic partnerships and initiatives are critical for future growth:
- Research and Development: Increased focus on R&D with expenses rising to $10.4 million for the nine months ended September 28, 2024, indicating a commitment to innovation.
- Market Diversification: The company is exploring new geographical markets, which is reflected in a 10.2% increase in international net sales.
Competitive Advantages that Position the Company for Growth
Bioventus enjoys several competitive advantages that bolster its growth potential:
- Established Product Portfolio: The company has a well-diversified product line that includes Pain Treatments, Restorative Therapies, and Surgical Solutions, which collectively generated $138.9 million in sales for Q3 2024.
- Strong Gross Margins: The gross profit margin for the U.S. segment improved to 68.2%, up from 65.9% the previous year, highlighting operational efficiency.
Conclusion
The financial health of Bioventus Inc. reflects a company strategically positioned for growth through product innovation, market expansion, and effective management of its resources.
Bioventus Inc. (BVS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Bioventus Inc. (BVS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Bioventus Inc. (BVS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Bioventus Inc. (BVS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.